title: Imaging-guided percutaneous radiofrequency ablation of retroperitoneal metastatic disease in patients with gynecologic malignancies: clinical experience with eight patients.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the efficacy of imaging-guided percutaneous radiofrequency ablation to treat metastatic retroperitoneal disease in patients with gynecologic malignancies.
  
  
  METHODS
  Patients with retroperitoneal metastatic disease due to gynecologic malignancies were evaluated for imaging-guided percutaneous radiofrequency ablation in this study. Efficacy of treatment was assessed by post-radiofrequency ablation activity on PET/CT scans.
  
  
  RESULTS
  Eight patients were considered for imaging-guided percutaneous radiofrequency ablation of retroperitoneal metastatic disease. Radiofrequency ablation was successfully completed in five patients with six metastatic tumors. All procedures were performed with the use of hydrodissection as an adjunct maneuver to displace adjacent structures. All patients showed absence of FDG activity on post-radiofrequency ablation PET/CT scans. Three (60%) of the five patients showed absence of FDG activity of the treated disease at 23.5 months after radiofrequency ablation.
  
  
  CONCLUSIONS
  Imaging-guided percutaneous radiofrequency ablation may be considered as an alternative to currently available therapies to treat recurrent metastatic disease due to endometrial carcinoma.
authors.affiliation: Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Boston, MA 02114, USA. rarellano@partners.org
authors.forename: Ronald S
authors.initials: RS
authors.lastname: Arellano
authors.forename: Vincent L
authors.initials: VL
authors.lastname: Flanders
authors.forename: Susanna I
authors.initials: SI
authors.lastname: Lee
authors.forename: Peter R
authors.initials: PR
authors.lastname: Mueller
authors.forename: Debra A
authors.initials: DA
authors.lastname: Gervais
mesh_terms: D000368:Aged; D017115:Catheter Ablation / Q000379:methods*; D017024:Chemotherapy, Adjuvant; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery*; D015641:Radiography, Interventional; D019275:Radiopharmaceuticals; D012186:Retroperitoneal Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary* / Q000601:surgery*; D012189:Retrospective Studies; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18